# Tempus AI Acquires Personalis for $1.5B to Integrate MRD Technology Into Precision Oncology Platform

> ma · REPORTED · 2026-07-20

Tempus AI announced a definitive agreement to acquire Personalis at $16.25 per share, representing a total enterprise value of $1.5 billion net of Tempus's existing ownership stake, with closing targeted for late 2026 or early 2027. The deal integrates Personalis's ultrasensitive NeXT Personal MRD cancer monitoring technology into Tempus's AI-enabled oncology data platform, targeting a U.S. MRD market exceeding $20 billion.

About Tempus AI: Tempus AI is a precision medicine technology company that applies artificial intelligence to genomic sequencing, multimodal clinical data, and AI applications to help physicians deliver personalized cancer care and accelerate drug discovery.

- Company: Tempus AI
- Sector: oncology
- Primary source: https://investors.tempus.com/news-releases/news-release-details/tempus-acquire-personalis-more-tightly-integrating-molecular

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.